Skip to main content
SpringerLink
Log in

Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The current review covers extant literature on pharmacotherapy for core symptoms of autism. The core symptoms of autism include impairments in social interaction and communication, as well as the presence of restricted and repetitive behaviors. There are no known efficacious treatments for the core social symptoms, although effects on repetitive behaviors are indicated with some data. While studies of fenfluramine, secretin, opiates, and mood stabilizers generally find no effect, mixed results suggest more research is needed on antidepressants and atypical antipsychotics. Newer lines of research, including cholinergic and glutamatergic agents and oxytocin, will be of considerable interest in the future. However, research on the treatment of core symptoms is plagued by limitations in study design, statistical power, and other issues inherent to the study of treatments for autism (e.g., heterogeneity of the disorder) that continue to prevent the elucidation of efficacious treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Psychological Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington: American Psychiatric Association; 2000.

    Google Scholar 

  2. Lord C, Jones RM. Annual research review: re-thinking the classification of autism spectrum disorders. J Child Psychol Psychiatry. 2012;53(5):490–509.

    Article  PubMed  Google Scholar 

  3. Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord. 2003;33(5):527–34.

    Article  PubMed  Google Scholar 

  4. Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J, Polsky DE. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics. 2008;121(3):e441–8.

    Article  PubMed  Google Scholar 

  5. Siegel M, Beaulieu AA. Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice. J Autism Dev Disord. 2012;42(8):1592–605.

    Article  PubMed  Google Scholar 

  6. Lecavalier L, Aman MG, Hammer D, Stoica W, Mathews GL. Factor analysis of the Nisonger child behavior rating form in children with autism spectrum disorders. J Autism Dev Disord. 2004;34(6):709–21.

    Article  PubMed  Google Scholar 

  7. Leyfer OT, Folstein SE, Bacalman S, Davis NO, Dinh E, Morgan J, et al. Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord. 2006;36(7):849–61.

    Article  PubMed  Google Scholar 

  8. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47(8):921–9.

    Article  PubMed  Google Scholar 

  9. Farmer CA, Aman MG. Aripiprazole for the treatment of irritability associated with autism. Expert Opin Pharmacother. 2011;12(4):635–40.

    Article  PubMed  CAS  Google Scholar 

  10. Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs. 2007;9(5):343–54.

    Article  PubMed  Google Scholar 

  11. Doyle CA, McDougle CJ. Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opin Pharmacother. 2012;13(11):1615–29.

    Article  PubMed  CAS  Google Scholar 

  12. Cook EH, Leventhal BL. The serotonin system in autism. Curr Opin Pediatr. 1996;8(4):348–54.

    Article  PubMed  CAS  Google Scholar 

  13. Geller E, Ritvo ER, Freeman BJ, Yuwiler A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med. 1982;307(3):165–9.

    Article  PubMed  CAS  Google Scholar 

  14. Ritvo ER, Freeman BJ, Yuwiler A, Geller E, Schroth P, Yokota A, et al. Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacol Bull. 1986;22(1):133–40.

    PubMed  CAS  Google Scholar 

  15. Campbell M, Adams P, Small AM, Curren EL, Overall JE, Anderson LT, et al. Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry. 1988;27(4):434–9.

    Article  PubMed  CAS  Google Scholar 

  16. Stern LM, Walker MK, Sawyer MG, Oades RD, Badcock NR, Spence JG. A controlled crossover trial of fenfluramine in autism. J Child Psychol Psychiatry. 1990;31(4):569–85.

    Article  PubMed  CAS  Google Scholar 

  17. Leventhal BL, Cook EH, Morford M, Ravitz AJ, Heller W, Freedman DX. Clinical and neurochemical effects of fenfluramine in children with autism. J Neuropsychiatr Clin Neurosci. 1993;5(3):307–15.

    CAS  Google Scholar 

  18. Sherman J, Factor DC, Swinson R, Darjes RW. The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children. J Autism Dev Disord. 1989;19(4):533–43.

    Article  PubMed  CAS  Google Scholar 

  19. Panksepp J, Najam N, Soares F. Morphine reduces social cohesion in rats. Pharmacol Biochem Behav. 1979;11(2):131–4.

    Article  PubMed  CAS  Google Scholar 

  20. Elchaar GM, Maisch NM, Augusto LM, Wehring HJ. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother. 2006;40(6):1086–95.

    Article  PubMed  CAS  Google Scholar 

  21. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry. 1993;32(6):1283–91.

    Article  PubMed  CAS  Google Scholar 

  22. Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, van Engeland H. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res. 1995;58(3):203–15.

    Article  PubMed  CAS  Google Scholar 

  23. Bouvard MP, Leboyer M, Launay JM, Recasens C, Plumet MH, Waller-Perotte D, et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res. 1995;58(3):191–201.

    Article  PubMed  CAS  Google Scholar 

  24. Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys. 1998;9(1):9–15.

    PubMed  CAS  Google Scholar 

  25. Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003495.

  26. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry. 2001;62(7):530–4.

    Article  PubMed  CAS  Google Scholar 

  27. Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol. 2006;9(2):209–13.

    Article  PubMed  CAS  Google Scholar 

  28. Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, et al. Children’s Yale-Brown obsessive compulsive scale: reliability and validity. J Am Acad Child Adolesc Psychiatry. 1997;36(6):844–52.

    Article  PubMed  CAS  Google Scholar 

  29. Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010;35(4):990–8.

    Article  PubMed  CAS  Google Scholar 

  30. Yasuhara A. Correlation between EEG abnormalities and symptoms of autism spectrum disorder (ASD). Brain Dev. 2010;32(10):791–8.

    Article  PubMed  Google Scholar 

  31. Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2001;31(2):175–81.

    Article  PubMed  CAS  Google Scholar 

  32. Wasserman S, Iyengar R, Chaplin WF, Watner D, Waldoks SE, Anagnostou E, et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 2006;21(6):363–7.

    Article  PubMed  Google Scholar 

  33. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–21.

    Article  Google Scholar 

  34. Aman M, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89(5):485–91.

    PubMed  CAS  Google Scholar 

  35. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005;162(6):1142–8.

    Article  PubMed  Google Scholar 

  36. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):E634–41.

    Article  PubMed  Google Scholar 

  37. Aman MG, Tasse MJ, Rojahn J, Hammer D. The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Res Dev Disabil. 1996;17(1):41–57.

    Article  PubMed  CAS  Google Scholar 

  38. Scahill L, Hallet T, Aman M, Arnold LE, McDougle C, McCracken J, et al. Brief report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. J Autism Dev Disord. 2013;24(3):739–46.

    Google Scholar 

  39. Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1143–54.

    Article  PubMed  Google Scholar 

  40. Sparrow S, Balla D, Cicchetti D. Vineland adaptive behavior scales: survey form manual. Circle Pines: American Guidance Service; 1984.

    Google Scholar 

  41. Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl). 2012;223(2):237–45.

    Article  CAS  Google Scholar 

  42. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110–9.

    Article  PubMed  Google Scholar 

  43. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533–40.

    Article  PubMed  Google Scholar 

  44. Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry. 2011;72(9):1270–6.

    Article  PubMed  CAS  Google Scholar 

  45. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50(6):441–7.

    Article  PubMed  CAS  Google Scholar 

  46. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl. 1978;271:5–27.

    Article  PubMed  Google Scholar 

  47. Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2001;21(4):440–4.

    Article  PubMed  CAS  Google Scholar 

  48. King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009;66(6):583–90.

    Article  PubMed  CAS  Google Scholar 

  49. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30(3):582–9.

    Article  PubMed  CAS  Google Scholar 

  50. Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry. 2012;169(3):292–9.

    Article  PubMed  Google Scholar 

  51. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996;53(11):1001–8.

    Article  PubMed  CAS  Google Scholar 

  52. Posey DJ, Erickson CA, Stigler KA, McDougle CJ. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol. 2006;16(1–2):181–6.

    Article  PubMed  Google Scholar 

  53. Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am. 2008;17(4):787–801.

    Article  PubMed  Google Scholar 

  54. Deutsch SI, Urbano MR, Neumann SA, Burket JA, Katz E. Cholinergic abnormalities in autism: is there a rationale for selective nicotinic agonist interventions? Clin Neuropharmacol. 2010;33(3):114–20.

    Article  PubMed  CAS  Google Scholar 

  55. Chez M, Buchanan T, Becker M, Kessler J, Aimonovitch M, Mrazek S. Donepezil hydrochloride: a double-blind study in autistic children. J Pediatr Neurol. 2003;1(2):83–8.

    CAS  Google Scholar 

  56. Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification of childhood autism: childhood Autism rating scale (CARS). J Autism Dev Disord. 1980;10(1):91–103.

    Article  PubMed  CAS  Google Scholar 

  57. Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 2002;12(3):237–41.

    Article  PubMed  Google Scholar 

  58. Doyle RL, Frazier J, Spencer TJ, Geller D, Biederman J, Wilens T. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord. 2006;9(3):543–9.

    Article  PubMed  Google Scholar 

  59. Buckley AW, Sassower K, Rodriguez AJ, Jennison K, Wingert K, Buckley J, et al. An open label trial of donepezil for enhancement of rapid eye movement sleep in young children with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2011;21(4):353–7.

    Article  PubMed  CAS  Google Scholar 

  60. Niederhofer H. Treating autism pharmacologically: also tacrine might improve symptomatology in some cases. J Child Neurol. 2007;22(8):1054. (author reply 1054–5).

    Article  PubMed  Google Scholar 

  61. Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004;19(3):165–9.

    PubMed  Google Scholar 

  62. Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol. 2006;16(5):621–9.

    Article  PubMed  Google Scholar 

  63. Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. BMJ. 2002;325(7377):1422.

    Article  PubMed  Google Scholar 

  64. Arnold LE, Aman MG, Hollway J, Hurt E, Bates B, Li X, et al. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. J Child Adolesc Psychopharmacol. 2012;22(3):198–205.

    Article  PubMed  CAS  Google Scholar 

  65. McDougle CJ, Erickson CA, Stigler KA, Posey DJ. Neurochemistry in the pathophysiology of autism. J Clin Psychiatry. 2005;66(Suppl 10):9–18.

    PubMed  CAS  Google Scholar 

  66. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, et al. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56(1):21–7.

    Article  PubMed  CAS  Google Scholar 

  67. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of d-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004;161(11):2115–7.

    Article  PubMed  Google Scholar 

  68. King BH, Wright DM, Handen BL, Sikich L, Zimmerman AW, McMahon W, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(6):658–65.

    Article  PubMed  CAS  Google Scholar 

  69. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2007;191(1):141–7.

    Article  PubMed  CAS  Google Scholar 

  70. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22(5):574–9.

    Article  PubMed  Google Scholar 

  71. Owley T, Salt J, Guter S, Grieve A, Walton L, Ayuyao N, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):517–24.

    Article  PubMed  Google Scholar 

  72. Niederhofer H. Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. J Clini Psychopharmacol. 2007;27(3):317–8.

    Article  Google Scholar 

  73. Erickson CA, Early M, Stigler KA, Wink LK, Mullett JE, McDougle CJ. An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. J Child Adolesc Psychopharmacol. 2011;21(6):565–9.

    Article  PubMed  CAS  Google Scholar 

  74. Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with Autism. Biol Psychiatry. 2012;71(11):956–61.

    Article  PubMed  CAS  Google Scholar 

  75. Chadman KK, Guariglia SR, Yoo JH. New directions in the treatment of autism spectrum disorders from animal model research. Expert Opin Drug Discov. 2012;7(5):407–16.

    Article  PubMed  CAS  Google Scholar 

  76. Insel TR. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron. 2010;65(6):768–79.

    Article  PubMed  CAS  Google Scholar 

  77. Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010;67(7):692–4.

    Article  PubMed  CAS  Google Scholar 

  78. Ellenbogen MA, Linnen AM, Grumet R, Cardoso C, Joober R. The acute effects of intranasal oxytocin on automatic and effortful attentional shifting to emotional faces. Psychophysiology. 2012;49(1):128–37.

    Article  PubMed  Google Scholar 

  79. Rimmele U, Hediger K, Heinrichs M, Klaver P. Oxytocin makes a face in memory familiar. J Neurosci. 2009;29(1):38–42.

    Article  PubMed  CAS  Google Scholar 

  80. Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology. 2003;28(1):193–8.

    Article  PubMed  CAS  Google Scholar 

  81. Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2007;61(4):498–503.

    Article  PubMed  CAS  Google Scholar 

  82. Sandler AD, Bodfish JW. Placebo effects in autism: lessons from secretin. J Dev Behav Pediatr. 2000;21(5):347–50.

    Article  PubMed  CAS  Google Scholar 

  83. Gelenberg AJ, Thase ME, Meyer RE, Goodwin FK, Katz MM, Kraemer HC, et al. The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry. 2008;69(10):1513–28.

    Article  PubMed  Google Scholar 

  84. Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, et al. Epigenetic modification of the FMR1 gene in Fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011;3(64):64ra1.

    Article  PubMed  CAS  Google Scholar 

  85. Aman MG, Novotny S, Samango-Sprouse C, Lecavalier L, Leonard E, Gadow KD, et al. Outcome measures for clinical drug trials in autism. CNS Spectr. 2004;9(1):36–47.

    PubMed  Google Scholar 

  86. Lord C, Rutter M, Le Couteur A. Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24(5):659–85.

    Article  PubMed  CAS  Google Scholar 

  87. Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30(3):205–23.

    Article  PubMed  CAS  Google Scholar 

  88. Scahill L, McDougle CJ, Williams SK, Dimitropoulos A, Aman MG, McCracken JT, et al. Children’s Yale-Brown obsessive compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2006;45(9):1114–23.

    Article  PubMed  Google Scholar 

  89. Indah Winarni T, Chonchaiya W, Adams E, Au J, Mu Y, Rivera SM, et al. Sertraline may improve language developmental trajectory in young children with Fragile X syndrome: a retrospective chart review. Autism Res Treat. 2012;2012:104317.

    PubMed  Google Scholar 

  90. Kobak KA, Kane JM, Thase ME, Nierenberg AA. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol. 2007;27(1):1–5.

    Article  PubMed  Google Scholar 

  91. Krueger DD, Bear MF. Toward fulfilling the promise of molecular medicine in Fragile X syndrome. Annu Rev Med. 2011;62:411–29.

    Article  PubMed  CAS  Google Scholar 

  92. Scahill L, McCracken JT, Bearss K, Robinson F, Hollander E, King B, et al. Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. J Autism Dev Disord. 2012;42(3):432–40.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Intramural Program of the National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH). The views expressed in this article do not necessarily represent the views of the NIMH, NIH, the Department of Health and Human Services, or the United States Government. The authors have no conflicts of interest to report.

Author information

Authors and Affiliations

  1. Pediatrics and Developmental Neuroscience Branch, National Institute of Mental Health, 10 Center Drive MSC 1255, Building 10, Room 1C250, Bethesda, MD, 20892-1255, USA

    Cristan Farmer, Audrey Thurm & Paul Grant

Authors
  1. Cristan Farmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Audrey Thurm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Grant
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cristan Farmer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Farmer, C., Thurm, A. & Grant, P. Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research. Drugs 73, 303–314 (2013). https://doi.org/10.1007/s40265-013-0021-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-013-0021-7

Keywords

Search

Navigation